DE69533128D1 - Pharmazeutische akzeptabel dnase zusammensetzung - Google Patents

Pharmazeutische akzeptabel dnase zusammensetzung

Info

Publication number
DE69533128D1
DE69533128D1 DE69533128T DE69533128T DE69533128D1 DE 69533128 D1 DE69533128 D1 DE 69533128D1 DE 69533128 T DE69533128 T DE 69533128T DE 69533128 T DE69533128 T DE 69533128T DE 69533128 D1 DE69533128 D1 DE 69533128D1
Authority
DE
Germany
Prior art keywords
dnase
lung
pharmaceutical acceptable
formulations
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533128T
Other languages
English (en)
Other versions
DE69533128T2 (de
Inventor
Hak-Kim Chan
R Clark
Igor Gonda
C Hsu
Marco Mumenthaler
J Shire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69533128D1 publication Critical patent/DE69533128D1/de
Application granted granted Critical
Publication of DE69533128T2 publication Critical patent/DE69533128T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69533128T 1994-03-04 1995-02-28 Pharmazeutische akzeptabel dnase zusammensetzung Expired - Lifetime DE69533128T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20602094A 1994-03-04 1994-03-04
US206020 1994-03-04
US36407494A 1994-12-27 1994-12-27
US364074 1994-12-27
PCT/US1995/002041 WO1995023613A1 (en) 1994-03-04 1995-02-28 PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION

Publications (2)

Publication Number Publication Date
DE69533128D1 true DE69533128D1 (de) 2004-07-15
DE69533128T2 DE69533128T2 (de) 2005-06-09

Family

ID=26900974

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533128T Expired - Lifetime DE69533128T2 (de) 1994-03-04 1995-02-28 Pharmazeutische akzeptabel dnase zusammensetzung

Country Status (6)

Country Link
EP (1) EP0748225B1 (de)
JP (1) JP2986215B2 (de)
AT (1) ATE268605T1 (de)
CA (1) CA2184582C (de)
DE (1) DE69533128T2 (de)
WO (1) WO1995023613A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9814172D0 (en) * 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DE60227691D1 (de) 2001-11-01 2008-08-28 Nektar Therapeutics Sprühtrocknungsverfahren
CA2468958C (en) 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
ES2527096T3 (es) * 2002-02-18 2015-01-20 Ockham Biotech Limited Combinación de ADNasa I y glucosaminoglucanos para su uso en limpieza de ADN extracelular
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
EP1880733A4 (de) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Verfahren zur verlängerung der lebensdauer eines menschen und von tieren
JP5372769B2 (ja) 2006-11-28 2013-12-18 シーエルエス セラピューティック リミティド 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤
WO2009120619A2 (en) * 2008-03-24 2009-10-01 Novartis Ag Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
CN102292072A (zh) 2009-01-26 2011-12-21 特瓦制药工业有限公司 用微粒包衣载体的方法
WO2011038901A1 (en) * 2009-09-29 2011-04-07 Activaero Gmbh Improved method for treatment of patients with cystic fibrosis
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233405A (en) * 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
DE68929551T2 (de) * 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
JPH04271785A (ja) * 1991-02-28 1992-09-28 Kao Corp 酵素固形製剤及びその製造方法
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Also Published As

Publication number Publication date
CA2184582C (en) 2001-12-25
EP0748225A1 (de) 1996-12-18
CA2184582A1 (en) 1995-09-08
JPH09509927A (ja) 1997-10-07
DE69533128T2 (de) 2005-06-09
WO1995023613A1 (en) 1995-09-08
EP0748225B1 (de) 2004-06-09
JP2986215B2 (ja) 1999-12-06
ATE268605T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
ATE268605T1 (de) Pharmazeutische akzeptabel dnase zusammensetzung
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
MY117892A (en) Therapeutic compounds
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
DE69104830D1 (de) Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.
BR9610059A (pt) Método para detectar doença pulmomar
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
RU94002475A (ru) Фармацевтическая композиция и ее применение для лечения вирусных инфекций
RU94040170A (ru) Изохинолины
NO20001087L (no) Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer
SE9704833D0 (sv) New formulation
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
HUP0104410A2 (hu) Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
HUP9700806A2 (hu) Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
MX9805441A (es) Compuestos terapeuticos.
NZ505538A (en) A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
TNSN92115A1 (fr) Succedanes de benzimidazoles, processus de leur preparation ainsi que de leur utilisation
ATE141510T1 (de) Arzneimittel enthaltend cd14
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
RU94019564A (ru) Способ лечения желудочно-кишечных заболеваний
Torres New saquinavir formulation enters clinical trials

Legal Events

Date Code Title Description
8364 No opposition during term of opposition